Particularly, the overexpression of CRBN/RBX1 exemplified the potential therapeutic implication of lenalidomide, a CRBN/RBX1 inhibitor, in patients with severe COVID-19, where the CRBN/RBX1 inhibitor was reported as protective against severe COVID-19 in several patients with myeloma whose standard of care included lenalidomide [37]. This evidence concerns the gene CRBN and plasma cell myeloma.